ADVFN - Advanced Financial Network.
HOME» NYSE » A » AGN Stock Price » AGN Stock News

Allergan Share News

 Allergan, Stock Price
AGN Stock Price
 Allergan, Stock Chart
AGN Stock Chart
 Allergan, Stock News
AGN Stock News
 Allergan, Company Information
AGN Company Information
 Allergan, Stock Trades
AGN Stock Trades

Inspire Pharma: Dry-Eye Treatment Didn't Meet Study Endpoints

DOW JONES NEWSWIRES Inspire Pharmaceuticals Inc. (ISPH) said its Prolacria treatment for dry eye met neither the primary nor secondary endpoints in a late-stage trial. Shares fell 7.5% to $6.11 premarket. Shares in its partner in developing the eye drops, Allergan Inc. (AGN), weren't active after closing Wednesday at $61.20. Early data about Prolacria had been discouraging, so the final results won't come as a huge surprise, but the treatment had been one of Inspire's most advanced drugs in its pipeline. Its other advanced drug candidate is denufosol tetrasodium for cystic fibrosis. Inspire focuses on developing treatments for ophthalmic and pulmonary diseases. Chief Executive Christy Shaffer said Inspire has reported the results to Allergan and "will be conducting a thorough review of the program before determining next steps, if any." At the end of the six-week study, Inspire gauged subjects extent of dry eye with a "staining score," in which patterns made by a stain are used to measure damaged cells in the central area of the cornea. It aimed to have a proportion of its subjects receiving Prolacria have a staining score of zero compared to a placebo group, its primary endpoint. It also failed to reduce the staining score by two units compared to the control group, the secondary endpoint. Dry eye occurs when the eye isn't being sufficiently lubricated. In November, the drug company reported a narrower third-quarter loss thanks to double-digit growth in sales. -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291; [email protected]

Stock News for Allergan (AGN)
02/22/201708:01:00Allergan to Sponsor Alzheimer's Foundation of America '15th Anniversary...
02/15/201707:00:00Medicines360 And Allergan Announce Partnership With Health Centers...
02/14/201717:52:07Statement of Ownership (sc 13g)
02/14/201716:57:39Statement of Ownership (sc 13g)
02/13/201709:13:00Allergan to Buy Fat Treatment Maker Zeltiq for $2.3 Billion
02/13/201708:00:00Allergan to Acquire ZELTIQ, Best-in-Class Company in Fast-Growing...
02/09/201716:15:00Allergan to Present at The Leerink Partners 6th Annual Global...
02/09/201712:00:00AASLD Foundation's Liver Disease Research and Education Initiatives...
02/09/201709:54:50Schedule 13g
02/09/201706:06:07Amended Statement of Ownership (sc 13g/a)
02/08/201711:39:00Allergan Results Boosted by New, Established Drugs -- Update
02/08/201711:00:00Allergan Results Boosted by New, Established Drugs
02/08/201707:16:37Current Report Filing (8-k)
02/08/201707:00:00Allergan Reports Strong 2016 Finish with 7% Increase in GAAP...
02/07/201707:55:00Allergan Launches See America(SM), a Bold Initiative Furthering...
02/06/201713:33:34Amended Statement of Ownership (sc 13g/a)
02/03/201708:42:28Current Report Filing (8-k)
02/03/201707:45:00Allergan Declares First Quarterly Cash Dividend of $0.70 Per...
02/03/201707:30:00Allergan Provides Board and Annual Shareholder Meeting Updates
02/01/201708:00:00Allergan Successfully Completes LifeCell Acquisition

Allergan and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations